Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Melanoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Melanoma
    TopAbstracts in Melanoma 10/21/2009 - (DGNews)
    TopAbstracts in Melanoma 09/23/2009 - (DGNews)
    Study Reveals New Genetic Mutations Involved in Melanoma - (DGNews)
    TopAbstracts in Melanoma 08/26/2009 - (DGNews)
    Budesonide Fails as Diarrhoea Prophylactic in Melanoma Patients Receiving Ipilimumab - (DGNews)

    News archive

     Recent webcasts/CME - Melanoma
    • Moving Beyond Standard Therapy in Malignant Melanoma: Novel Agents and Combinations
    • Adjuvant Interferon Therapy Prolongs Relapse-Free Interval and Survival in Melanoma
    • Rational Vaccine Strategies May Better Harness the Immune System for Anticancer Response in Melanoma
    • Response May Not Be an Appropriate Endpoint for Evaluating Benefit From CTLA-4 Antagonists in Melanoma
    • Emerging Strategies for the Treatment of Metastatic Melanoma: The Role of Monoclonal Antibodies in Targeted Immunotherapy

      Webcasts/CME archive

       Recent cases - Melanoma
        Diffuse Anorectal Melanoma; Review of the Current Diagnostic and Treatment Aspects Based on a Case Report
        Malignant Melanoma Associated with a Blue Naevus: A Case Report
        Metastatic Malignant Melanoma of the Conjunctiva: A Case Report
        Delayed Malignant Melanoma Recurrence Simulating Primary Ovarian Cancer
        A 90-Year-Old Woman with an Asymptomatic Spot on Her Cheek

        Cases archive
          




        my personal edition > melanoma > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Shave Biopsy Negatively Affects Melanoma Treatment Decision Making: Presented at SSO

        By Crystal Phend

        SAN DIEGO, C.A. -- March 27, 2006 -- Although shave biopsies are often used in an attempt to remove the entire melanoma, excisional biopsy should be the preferred biopsy method, researchers said here at the annual meeting of the Society of Surgical Oncology (SSO).

        "The standard should be excisional biopsy," said presenting author Richard L. White, Jr., MD, chief of the division of surgical oncology, Carolinas Medical Center, Charlotte, North Carolina, United States. "If you are going to do a shave biopsy, you need to make it a much thicker biopsy."

        Dr. White and colleagues reviewed 223 cases of primary melanoma with known method of biopsy. Margins from the biopsies were either indicated on the pathology report or reviewed from specimen slides.

        Fifty-one of the patients had excisional biopsy while 44 had a punch biopsy and 128 had a shave biopsy.

        Although shave biopsy was by far the most common method, it also had the highest percentage of deep (more than 1 mm) positive margins at 22%, and a high percentage of positive margins overall at 50%.

        "The presence of positive margins and in particular the presence of deep positive margins, in such a large percentage of the shave biopsy specimens compromises the ability of this technique to properly stage patients," Dr. White said. This could compromise appropriate treatment recommendations as well, he added.

        Comparatively, excisional biopsy had the lowest number of positive margins (16%) and no deep positive margins. Punch biopsy also had no deep positive margins but had the highest rate of positive margins (68%).

        "The presence of tumor at the margin of punch biopsies is an expected result, since this method is often used to diagnose lesions with a large diameter," Dr. White explained.

        Mean biopsy thickness was 3.19 mm for excisional biopsy, 3.58 mm for punch biopsy, and 1.41 mm for shave biopsy. The differences between methods were significant as were those between punch and shave biopsy.

        Dr. White added that the average depth for shave biopsy was "much, much too thin."


        [Presentation title: Method of Biopsy and Incidence of Positive Margins in Primary Melanoma. Poster 83]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send